Art of the deal: How India turned from 'Maharaja of tariffs' to global trade hub

India secured a set of major trade pacts and tariff concessions that materially ease near-term frictions: the US announced a rollback of punitive reciprocal tariffs on India to an 18% cap (from prior 25–50% peaks) with high-profile US purchase pledges (Trump cited up to $500bn), while India concluded a comprehensive India–EU FTA (claimed >99% duty‑free access by export value) and FTAs or CEPAs with the UK (99% tariff-free, pending ratification), New Zealand (eventual zero tariffs), UAE (~97% lines duty-free) and Oman (~98% lines duty-free). Key beneficiaries include labour‑intensive exporters (textiles, gems & jewellery, leather), pharmaceuticals, engineering goods, electronics and services; energy is pivotal too as US seeks to shift India away from discounted Russian crude toward US LNG/coal. Implementation risks — unclear timelines and product coverage on the US mini‑deal, rules of origin, standards, certification, and MSME readiness — leave execution and near-term trade flows uncertain despite strategically significant market access gains.

Analysis

Market structure: The deals (US mini-deal + EU/UK/Gulf FTAs) re-route Indian exports toward high‑margin Western markets and lock in tariff relief (US cap to 18% vs prior 25–50%), concentrating near‑term winners in labor‑intensive exporters (textiles, gems, pharma) and high‑tech services (IT, semiconductors). Competitive dynamics favor Indian suppliers over lower‑cost SE Asian producers for EU/UK quotas and create pricing power for Indian engineering and medical device firms that clear technical standards. Cross‑asset: expect INR strength (3–7% over 6–12 months), equity inflows into India (benefiting INDA/EPI), modest tightening in India 10y spreads (20–60bp compression vs EM peers) and upward pressure on crude differentials as Russia volumes reroute.

Risk assessment: Tail risks include US implementation backtracking (political risk ahead of elections), onerous rules‑of‑origin and compliance delays that could push benefits out 12–24 months, and a global demand shock that negates export gains. Immediate (days) risk: headline reversal or missing joint statement increases FX and equity volatility; short term (weeks–months): re‑rating as details emerge; long term (years): structural GVC reconfiguration if MSME readiness fails. Hidden dependencies: certification capacity, state‑level export support, and energy costs (if India keeps buying discounted Russian oil, friction persists). Key catalysts: joint statement within 30 days, tariff schedule publication, EU/UK ratifications (UK by late 2026).

trade implications: Direct plays: overweight India via ETFs (INDA, EPI) and select IT exporters (INFY, HCLT) with 6–12 month horizons; pair trade India vs Vietnam (long INDA, short VNM/EEM) to capture share shifts. Options: buy 3–6 month call spreads on INDA targeting +15–25% upside to limit premium, and buy USD/INR puts (INR calls) for 3–9 month tenors if cost <1.5% notional. Sector rotation: increase allocation to Indian textiles, pharma, capital goods and testing/certification services; reduce exposure to low‑value SE Asian exporters and Russian energy index exposure.

contrarian angles: The market may price in fast implementation but forgets execution friction — rules‑of‑origin and certification could delay >12 months and transfer gains to large corporates, not MSMEs. INR appreciation is likely but could compress rupee‑reported revenues for exporters (counterintuitive short pressure on some IT names if appreciation >5%). Historical parallels: post‑FTA surges often saw initial export paperwork friction and only gradual volume ramp (EC‑Mercosur style). Unintended consequence: faster FTA‑led import liberalization could increase competition for domestic consumer goods, compressing margins for protected incumbents.

Key Decisions for Investors

• Establish a 2–3% portfolio long position in INDA (iShares MSCI India) and a 1–2% satellite position in EPI (WisdomTree India Earnings) with a 6–12 month horizon; increase allocation to 4–5% combined if a joint US‑India tariff schedule is published within 30 days confirming ≤18% across >70% US tariff lines.
• Buy 0.5–1.0% positions each in INFY (Infosys) and HCLT (HCL Technologies) as plays on high‑tech services/nearshoring; set target +20% and stop‑loss at -12% within 9–12 months, because services and semiconductor cooperation are explicit winners.
• Implement a relative‑value pair: long INDA (1.5%) / short VNM or EEM (1.5%) to capture re‑routing of apparel/engineering exports to EU/UK; target 8–15% relative outperformance in 6–12 months and unwind if INDA underperforms by >8% in 90 days.
• Deploy options: buy a 3–6 month INDA call spread (buy ATM, sell +15% strike) sized to cap premium to ~0.5–1.0% portfolio risk; simultaneously buy 3–9 month USD/INR put options (INR calls) equal to anticipated INR exposure to hedge FX at cost ≤1.5% notional, expecting 3–7% INR appreciation.
• Reduce 3–6 month exposure (trim 20–30%) to small EM exporters with heavy China/Gulf concentration and to commodity names exposed to Russian trade flows; redeploy proceeds into Indian capital goods, certification/testing service providers, and local‑currency Indian sovereign bond funds targeting 6.5–7.5% yields over 12–24 months.